idc btig estim compani document
million except per share amount
song remain analyst day bring surpris
edward deliv bullish overview
compani multi-prong platform tavr mitral surgeri market
although neither substanti updat strategi major product
announc narr remain reliabl consist tavr market
global opportun expect exceed estim could
prove conserv us effort acceler small center use captur
patient prior referr expand geograph prove success
nearer term prolifer low-risk patient new center addit lay
groundwork double-digit procedur growth whole lot new
mitral though diversifi portfolio continu advanc multipl front
two biggest announc today plan significantli re-do cardioband
approv first transsept pivot trial final initi fiscal
guidanc unveil sens investor brace possibl
ep rang could come light heel commentari around softer gross
margin anticip spend outlook howev within estim
consensu tavr guidanc come better street model
balanc investor day re-affirmed posit outlook tavr opportun
clinic progress transsept access import step right
direct think remain strong chanc compani could post solid
tavr beat back low-risk adopt howev share trade
ntm ep estim bump high tough justifi
meaning upsid core opportun alon without discern
progress mitral maintain neutral rate
still room run beyond current treatment paradigm within tavr
core market double-digit growth remain buoy indic expans
ncd chang manag confirm next-gen sapien valv
work fim complet pivot trial expect next month
one interest present came dr geoff strang
starkli poor long-term surviv among patient moder grow
bodi research support move toward earlier intervent
advanc mitral much learn process overal mitral
timelin steadi vs prior updat compani remain commit
cardioband annular reduct toolbox suggest need
design overhaul reduc procedur time improv outcom among
manufactur issu soften mitral result pascal
manag anticip approv sometim
tweak ep increas forecast tavr growth rate
trim gross margin net-net ep forecast inch
valuat share trade ntm ep estim view risk-reward
balanc gain comfort compani success
mitral space maintain neutral rate
edward rate neutral view edward well-round aortic mitral tricuspid portfolio
make competit long-term confid trans-sept mitral replac product
could closer previous estim howev feel share market cap price mani thing
go right bake success mitral program
stabl procedur growth price
expans current tam
cut reimburs
edward major market
surgic heart valv
multipl area critic care
three import
result stock trade almost
entir thv result
exhibit mitral tricuspid pipelin updat analyst day
therapyproductapproachfunct mitral repaircardiobandannular reductionfunct mitral repair degen mitral repairpascalleaflet repairdegen mitral repair surgic heart valv busi harpoon medicalb heart degen mitral dm repairtricuspid repairformaleaflet repairtricuspid repaircardiobandannular reductiontranssept mitral replacementsapien sapien addit dock devic anchor valvetranssept mitral replacementevoquetechnolog acquir analyst day commentaryreduc cardiaq valv profil make transsept deliveri system easier usewil studi improv system result ce mark trial present tct one year treat patient trace/mild mitral regurgit patient group mortal rate day us activ pivot trial enroll nowprior eu commerci enroll us trial enhanc product analyst day commentaryfirst evoqu case success complet tct success outcom among consecut patient follow year mr grade continu earli feasibl studi trial enroll cardioband activ mr halt evalu trial design post coapt base result shown tct durabl reduct mr signific qualiti life progress continu work fortifi product capabl reduc procedur time sapien platform use approxim mitral procedur includ mitral ring mitral valve-in-valv mitral annular calcif sapien mitral valve-in-valv fda approv sapien valve-in-r studi mitral trial sapien mitral annular calcif studi mitral sitral trial enroll pivot trial commenc late tct data patient earli clinic experi present show high technic success reduct mr death caus day pivot trial initi late result studi shown tctce mark trial enroll ce mark eu launch slate earli feasibl studi slate start tr pivot trial enrol late result shown tctthe clasp ce mark trial us earli feasibl studi enroll noweu launch slate europ enroll pascal clasp dmr pivot trial clasp iid random pascal vs mitraclip enroll commenc pascal clasp fmr pivot trial clasp iif late trial design random vs mitraclip reveal tricuspid earli feasibl studi enrolllingbas six-month outcom publish lancet among patient mr investig observ signific qualiti life improv pascal also shown safe feasibl high-risk/inoper patient patient treat decemb ew announc acquisit increment mileston reach year use transap approach perform beating-heart surgeri anticip asp estim patient candid harpooncompani integr product commerci europ expect treatabl popul could total europ japan manag realiz limit case chord ruptur could correct proper techniqu rather design fix expect treat patient europ patient undergon result shown tctsystem improv expect start perform procedur improv system tct data patient implant first gener data show signific reduct tricuspid regurgit sustain cardiac function qualiti life improv one year continu earli feasibl studi updat devic inform futur clinic regulatori plan analyst day updatewil focu creation next-gen cardioband prior initi random trial limit detail provid management outsid focus cut procedur time one hour per tct updat patient continu commerci treat eu miband post-market studi continu enroll meanwhil pivot trial pend reevalu heel coapt procedur enhanc enroll tricuspid earli feasibl studi continu enroll clasp studi complet clasp iid year-end follow-up commentari target approv anticip ce mark approv year-end juli compani announc discontinu platform tct data patient experi present day present reveal technic success success access deploy posit well signific annular tr sever reduct sustain addit patient experienc clinic signific improv function statu qol enrol tricuspid earli feasibl studi analyst day announc approv first transsept pivot trial enrol detail clinic trial made public analyst day tct data patient experi present day technic success achiev patient one death patient achiev mr reduct day procedur durat minut continu enroll mitral earli feasibl studi initi tricuspid earli feasibl studi tct clinic outcom day present patient day mr fell stabl lvef patient addit patient experienc clinic signific improv nyha function class lastli skin-to-skin procedur time averag minut
edward incom revenu inc thv return y/i good gross sg other- total oper oper incom ex interest interest expens pre-tax incom tax non-gaap net non-gaap share ex marginsgross net total total total oper tax ep btig estim compani report
edward gaap revenu us y/i ou y/i y/i broken y/i tmtt y/i heart valv y/i y/i gaap net y/i non-gaap revenu us y/i ou y/i y/i broken y/i tmtt y/i heart valv y/i y/i non-gaap net y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
